CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Bristol Myers BMY

Verkoop
 Koop

BristolMyers live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

BristolMyers news

number1 2025 Jul 11, 03:38

AI Podcast: Dollar Weakness and Investment Implications

number1 2025 Jul 11, 03:38

HSBC: Three 'Painful Trade' Risks Loom if Wall Street Gets It Wrong

number1 2025 Jul 11, 03:38

Turkey's $500 Billion Gold Hoard: Unlocking Economic Potential

Magnificent 7 earnings, US and Japan inflation due next week
Neil Wilson 2024 Jul 18, 16:00

Week ahead: Magnificent 7 earnings, 2 key inflation reports

Forex Indices
Wall Street earnings
Neil Wilson 2023 Oct 20, 10:00

Week ahead: Earnings bonanza, ECB decision & US inflation

Forex Indices
Megacap-tech-stocks.jpg
Neil Wilson 2023 Apr 21, 05:00

Week ahead: Megacap tech and 1-in-3 Dow components set to report

2022 Jul 24, 05:42

Week ahead: Fed to hike 100bps into a recession?

Laatste marktnieuws

Toon meer
number1 2025 Oct 21, 00:00

Zelenskyy Expresses Doubts About Budapest as Venue for Ukraine Peace Talks

number1 2025 Oct 21, 00:00

Europe Rallies Behind Ukraine Amid Trump Pressure, Eyes Frozen Russian Assets

number1 2025 Oct 21, 00:00

US Government Shutdown: Economic Fallout and Political Impasse

number1 2025 Oct 21, 00:00

Gold Price Surge Fueled by Fed Rate Cut Expectations and Economic Uncertainty

number1 2025 Oct 19, 00:00

Global Market Overview: Precious Metals Surge Amidst Economic Uncertainty

number1 2025 Oct 18, 00:00

Japan LDP-Ishin Policy Talks: Paving the Way for a New Prime Minister?

number1 2025 Oct 18, 00:00

Israel Prepares to Reopen Rafah Crossing Amid Ceasefire Violation Claims

number1 2025 Oct 18, 00:00

Fed's Rate Cut Conundrum: An Outlook to 2026

Info

Spread

0.33

Spread (%)

0.6369 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Vrijdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

105757376512

Uitstaande aandelen

2035753027

Datum winstcijfer (volgende)

2001-08-07

Div. rend.

2025-11-03

Ex-dividenddatum

2025-10-03

Jaarlijks verwachte dividendpercentage

2.48

Jaarlijks verwachte dividendrendement

0.0487

Winst per aandeel

2.97

Meer informatie over dit instrument

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten

latest_education_articles

Toon meer
Frances Wang 2025 Feb 17, 16:00

Pi network price prediction 2025: Will Pi Network price go up or down?

Stocks
Frances Wang 2025 Jan 21, 16:00

What is the XRP price prediction for 2025: Will XRP reach $1000?

Crypto
Frances Wang 2024 Dec 29, 16:00

What is the USD DXY index and how does the DXY reflect the dollar's value?

Indices
Trustpilot